Clinical Trial Update: Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial testing atezolizumab or placebo with standard therapy as first-line treatment for HER2-positive metastatic breast cancer has completed, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2025-12-30